"Receptor, PAR-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A thrombin receptor subtype that couples to HETEROTRIMERIC GTP-BINDING PROTEINS resulting in the activation of a variety of signaling mechanisms including decreased intracellular CYCLIC AMP, increased TYPE C PHOSPHOLIPASES and increased PHOSPHOLIPASE A2.
| Descriptor ID |
D044463
|
| MeSH Number(s) |
D12.776.395.550.625.800.790 D12.776.543.550.625.800.790 D12.776.543.750.695.875.500 D12.776.543.750.705.675.892.790 D12.776.543.750.750.850.399 D12.776.543.750.792.500.500
|
| Concept/Terms |
Receptor, PAR-1- Receptor, PAR-1
- Receptor, PAR 1
- PAR1 Receptor
- Receptor, PAR1
- Protease-Activated Receptor 1
- Protease Activated Receptor 1
- PAR-1 Receptor
- PAR 1 Receptor
- Proteinase-Activated Receptor 1
- Proteinase Activated Receptor 1
|
Below are MeSH descriptors whose meaning is more general than "Receptor, PAR-1".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Glycoproteins [D12.776.395]
- Membrane Glycoproteins [D12.776.395.550]
- Platelet Membrane Glycoproteins [D12.776.395.550.625]
- Receptors, Thrombin [D12.776.395.550.625.800]
- Receptor, PAR-1 [D12.776.395.550.625.800.790]
- Membrane Proteins [D12.776.543]
- Membrane Glycoproteins [D12.776.543.550]
- Platelet Membrane Glycoproteins [D12.776.543.550.625]
- Receptors, Thrombin [D12.776.543.550.625.800]
- Receptor, PAR-1 [D12.776.543.550.625.800.790]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, G-Protein-Coupled [D12.776.543.750.695]
- Receptors, Thrombin [D12.776.543.750.695.875]
- Receptor, PAR-1 [D12.776.543.750.695.875.500]
- Receptors, Immunologic [D12.776.543.750.705]
- Platelet Membrane Glycoproteins [D12.776.543.750.705.675]
- Receptors, Thrombin [D12.776.543.750.705.675.892]
- Receptor, PAR-1 [D12.776.543.750.705.675.892.790]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Thrombin [D12.776.543.750.750.850]
- Receptor, PAR-1 [D12.776.543.750.750.850.399]
- Receptors, Proteinase-Activated [D12.776.543.750.792]
- Receptors, Thrombin [D12.776.543.750.792.500]
- Receptor, PAR-1 [D12.776.543.750.792.500.500]
Below are MeSH descriptors whose meaning is more specific than "Receptor, PAR-1".
This graph shows the total number of publications written about "Receptor, PAR-1" by people in this website by year, and whether "Receptor, PAR-1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, PAR-1" by people in Profiles.
-
Gremmel T, Michelson AD, Wadowski PP, Pultar J, Weikert C, Tscharre M, Lee S, Panzer S, Frelinger AL. Sex-specific platelet activation through protease-activated receptor-1 in patients undergoing cardiac catheterization. Atherosclerosis. 2021 12; 339:12-19.
-
Kuliopulos A, Gurbel PA, Rade JJ, Kimmelstiel CD, Turner SE, Bliden KP, Fletcher EK, Cox DH, Covic L. PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study. Arterioscler Thromb Vasc Biol. 2020 12; 40(12):2990-3003.
-
Rana R, Huang T, Koukos G, Fletcher EK, Turner SE, Shearer A, Gurbel PA, Rade JJ, Kimmelstiel CD, Bliden KP, Covic L, Kuliopulos A. Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis. Arterioscler Thromb Vasc Biol. 2018 06; 38(6):1368-1380.
-
Gremmel T, Michelson AD, Frelinger AL. In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization. Platelets. 2016 Jun; 27(4):308-16.
-
Barry KA, Somerville NJ. Vorapaxar (Zontivity) for the Prevention of Thrombotic Cardiovascular Events. Am Fam Physician. 2015 Aug 15; 92(4):304-5.
-
Frelinger AL, Grace RF, Gerrits AJ, Berny-Lang MA, Brown T, Carmichael SL, Neufeld EJ, Michelson AD. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood. 2015 Aug 13; 126(7):873-9.
-
Jabaiah AM, Getz JA, Witkowski WA, Hardy JA, Daugherty PS. Identification of protease exosite-interacting peptides that enhance substrate cleavage kinetics. Biol Chem. 2012 Sep; 393(9):933-41.
-
Michelson AD. Advances in antiplatelet therapy. Hematology Am Soc Hematol Educ Program. 2011; 2011:62-9.
-
Gramling MW, Beaulieu LM, Church FC. Activated protein C enhances cell motility of endothelial cells and MDA-MB-231 breast cancer cells by intracellular signal transduction. Exp Cell Res. 2010 Feb 01; 316(3):314-28.
-
Beaulieu LM, Church FC. Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1. Exp Cell Res. 2007 Feb 15; 313(4):677-87.